IDEAYA Biosciences (IDYA) Expected to Announce Earnings on Tuesday

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) is expected to announce its Q4 2024 earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.63) per share and revenue of $2.50 million for the quarter.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.86). On average, analysts expect IDEAYA Biosciences to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock traded up $0.24 during trading on Friday, reaching $21.00. The company had a trading volume of 1,427,577 shares, compared to its average volume of 881,663. The firm's 50-day simple moving average is $24.49 and its 200 day simple moving average is $30.11. IDEAYA Biosciences has a 1-year low of $20.63 and a 1-year high of $47.74. The firm has a market capitalization of $1.82 billion, a PE ratio of -9.01 and a beta of 0.82.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on IDYA shares. UBS Group started coverage on IDEAYA Biosciences in a report on Thursday, October 24th. They issued a "buy" rating and a $50.00 price objective on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Oppenheimer restated an "outperform" rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Leerink Partners lowered IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Finally, Leerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.